Related Experiment Video

Updated: Mar 19, 2026

Looking for Driver Pathways of Acquired Resistance to Targeted Therapy: Drug Resistant Subclone Generation and Sensitivity Restoring by Gene Knock-down
08:59

Looking for Driver Pathways of Acquired Resistance to Targeted Therapy: Drug Resistant Subclone Generation and Sensitivity Restoring by Gene Knock-down

Published on: December 11, 2017

7.7K

Novel approaches to target HER2-positive breast cancer: trastuzumab emtansine

Gonzalo Recondo1, Maximo de la Vega1, Fernando Galanternik1

  • 1Centro de Educación Médica e Investigaciones Clínicas, Buenos Aires, Argentina.

Cancer Management and Research
|June 9, 2016
PubMed

Insights

Trastuzumab emtansine (T-DM1) improves outcomes for HER2-positive breast cancer, especially when resistant to trastuzumab. This targeted therapy maximizes efficacy by delivering cytotoxic drugs directly to HER2-overexpressing cancer cells.

Area of Science:

  • Oncology
  • Pharmacology
  • Molecular Biology

Background:

  • HER2 is overexpressed in 20% of breast carcinomas, historically linked to aggressive disease and poor prognosis.
  • Targeted therapies have revolutionized HER2-positive breast cancer treatment.
  • Trastuzumab emtansine (T-DM1) is an antibody-drug conjugate targeting HER2-overexpressing cells.

Purpose of the Study:

  • To review the mechanism of action of T-DM1.
  • To summarize clinical trial data for T-DM1 in HER2-positive breast cancer.
  • To discuss ongoing research and future applications of T-DM1.

Main Methods:

  • Review of early and late-phase clinical trials involving T-DM1.
  • Analysis of T-DM1's mechanism of action as an antibody-drug conjugate.
  • Examination of ongoing studies in neoadjuvant and adjuvant settings.

Main Results:

  • T-DM1 enhances cytotoxic drug delivery to HER2-overexpressing cells, maximizing efficacy and minimizing toxicity.
  • T-DM1 has demonstrated improved outcomes in metastatic HER2-positive breast cancer resistant to trastuzumab.
  • Ongoing trials are evaluating T-DM1 in neoadjuvant and adjuvant settings.

Conclusions:

  • T-DM1 represents a significant advancement in treating HER2-positive breast cancer.
  • Its targeted mechanism offers improved efficacy and reduced toxicity.
  • Further research is exploring its role in various treatment settings for breast cancer.
Keywords:
HER2-positive breast cancerT-DM1metastatic breast cancertargeted therapiestrastuzumab emtansine

More Related Videos

High-Content Screening Assay for the Identification of Antibody-Dependent Cellular Cytotoxicity Modifying Compounds13:59

High-Content Screening Assay for the Identification of Antibody-Dependent Cellular Cytotoxicity Modifying Compounds

Published on: August 18, 2023

2.9K
Quantifying Antibody-Dependent Cellular Cytotoxicity in a Tumor Spheroid Model: Application for Drug Discovery13:19

Quantifying Antibody-Dependent Cellular Cytotoxicity in a Tumor Spheroid Model: Application for Drug Discovery

Published on: April 26, 2024

4.1K

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
9.1K
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

1.7K
Tumor Immunotherapy01:27

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
2.1K
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.9K
Mitogens and the Cell Cycle02:38

Mitogens and the Cell Cycle

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
8.3K
Cancer Vaccines01:30

Cancer Vaccines

Cancer treatment vaccines are a rapidly evolving field that offers a promising approach to immunotherapy. Unlike traditional vaccines that prevent diseases, cancer treatment vaccines are designed to treat existing cancers by stimulating the immune system to recognize and attack cancer cells.
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...
1.3K